Copyright
©The Author(s) 2015.
World J Gastrointest Pathophysiol. Nov 15, 2015; 6(4): 219-227
Published online Nov 15, 2015. doi: 10.4291/wjgp.v6.i4.219
Published online Nov 15, 2015. doi: 10.4291/wjgp.v6.i4.219
Drug | Trial | Study population | Protocol | Follow-up (wk) | Outcome |
Infliximab | ACT 1 Rutgeerts et al[5] | 121 | 5 mg/kg iv at 0, 2, 6, | 54 | 69.4% (P < 0.001) clinical response at week 8 |
and every 8 wk | 45.5% (P < 0.001) clinical response at week 54 | ||||
38.8% (P < 0.001) clinical remission at week 8 | |||||
34.7% (P = 0.001) clinical remission at week 54 | |||||
122 | 10 mg/kg iv at 0, 2, 6, | 54 | 61.5% (P < 0.001) clinical response at week 8 | ||
and every 8 wk | 44.3% (P < 0.001) clinical response at week 54 | ||||
32.0% (P = 0.002) clinical remission at week 8 | |||||
34.4% (P = 0.001) clinical remission at week 54 | |||||
ACT 2 Rutgeerts et al[5] | 121 | 5 mg/kg iv at 0, 2, 6, | 30 | 64.5% (P < 0.001) clinical response at week 8 | |
and every 8 wk | 47.1% (P < 0.001) clinical response at week 30 | ||||
33.9% (P < 0.001) clinical remission at week 8 | |||||
25.6% (P = 0.003) clinical remission at week 30 | |||||
120 | 10 mg/kg iv at 0, 2, 6, | 30 | 69.2% (P < 0.001) clinical response at week 8 | ||
and every 8 wk | 60.0% (P < 0.001) clinical response at week 30 | ||||
27.5% (P < 0.001) clinical remission at week 8 | |||||
35.8% (P < 0.001) clinical remission at week 30 | |||||
Adalimumab | ULTRA1 Reinisch et al[17] | 130 | 80/40 mg sc | 8 | 51.5% clinical response at week 8 |
80 mg at week 0, 40 mg at week 2, 4 and 6 | 10.0% (P = 0.833) clinical remission at week 8 | ||||
130 | 160/80 mg sc | 54.6% clinical response at week 8 | |||
160 mg at week 0, 80 mg at week 2, 40 mg at week 4 and 6 | 18.5% (P = 0.031) clinical remission at week 8 | ||||
ULTRA2 Sandborn et al[6] | 248 | 160/80 mg sc | 52 | 16.5% (P = 0.019) clinical remission at week 8 | |
160 mg at week 0, 80 mg at week 2, and then 40 mg every other week | 17.3% (P = 0.004) clinical remission at week 52 | ||||
ULTRA3 Colombel et al[18] | 360 | 40 mg sc every other week | 208 | 63.6% remission per partial Mayo score at week 208 | |
Golimumab | PURSUIT-SC[20] | 253 | 200/100 mg sc 2 wk apart | 6 | 51.6% (P < 0.0001) clinical response at week 6 |
17.8% (P < 0.0001) clinical remission at week 6 | |||||
257 | 400/200 mg sc 2 wk apart | 6 | 54.9% (P < 0.0001) clinical response at week 6 | ||
17.9% (P < 0.0001) clinical remission at week 6 | |||||
PURSUIT-M[7] | 151 | 50 mg sc every 4 wk | 54 | 47% (P = 0.010) clinical response at week 54 | |
23.2% clinical remission at week 54 | |||||
151 | 100 mg sc every 4 wk | 54 | 49.7% (P < 0.001) clinical response at week 54 | ||
27.8% (P = 0.004) clinical remission at week 54 |
- Citation: Akiho H, Yokoyama A, Abe S, Nakazono Y, Murakami M, Otsuka Y, Fukawa K, Esaki M, Niina Y, Ogino H. Promising biological therapies for ulcerative colitis: A review of the literature. World J Gastrointest Pathophysiol 2015; 6(4): 219-227
- URL: https://www.wjgnet.com/2150-5330/full/v6/i4/219.htm
- DOI: https://dx.doi.org/10.4291/wjgp.v6.i4.219